Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Bacterium or component thereof or substance produced by said...
Reexamination Certificate
2009-08-28
2011-11-08
Gupta, Anish (Department: 1654)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Bacterium or component thereof or substance produced by said...
C514S021200, C530S324000
Reexamination Certificate
active
08052980
ABSTRACT:
A method for treating a patient suffering from arthritis and associated pain include the administration to the patient of a therapeutically effective amount of a neurotoxic component of neurotoxin selected from a group consisting of Botulinum toxin types A, B, C, D, E, F and G.
REFERENCES:
patent: 4935969 (1990-06-01), Farnsworth
patent: 5298019 (1994-03-01), Borodic
patent: 5401243 (1995-03-01), Borodic
patent: 5512547 (1996-04-01), Johnson et al.
patent: 5562907 (1996-10-01), Arnon
patent: 5696077 (1997-12-01), Johnson et al.
patent: 5714468 (1998-02-01), Binder et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 6063768 (2000-05-01), First
patent: 6113915 (2000-09-01), Aoki et al.
patent: 6235289 (2001-05-01), Aoki et al.
patent: 6290961 (2001-09-01), Aoki et al.
patent: 6306403 (2001-10-01), Donovan
patent: 6319505 (2001-11-01), Aoki et al.
patent: 6333037 (2001-12-01), Aoki et al.
patent: 6372226 (2002-04-01), Aoki et al.
patent: 6395277 (2002-05-01), Graham
patent: 6448231 (2002-09-01), Graham
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6500436 (2002-12-01), Donovan
patent: 6623742 (2003-09-01), Voet
patent: 6683049 (2004-01-01), Aoki et al.
patent: 6841156 (2005-01-01), Aoki et al.
patent: 6872397 (2005-03-01), Aoki et al.
patent: 6887476 (2005-05-01), Aoki et al.
patent: 6896886 (2005-05-01), Aoki et al.
patent: 6939852 (2005-09-01), Graham
patent: 6974578 (2005-12-01), Aoki et al.
patent: 7091176 (2006-08-01), Aoki et al.
patent: 7381700 (2008-06-01), Aoki et al.
patent: 2001/0018415 (2001-08-01), Aoki et al.
patent: 2002/0102275 (2002-08-01), Graham
patent: 2003/0118598 (2003-06-01), Hunt
patent: 2004/0014663 (2004-01-01), Aoki et al.
patent: 2004/0126396 (2004-07-01), Aoki et al.
patent: 2004/0126397 (2004-07-01), Aoki et al.
patent: 2004/0151740 (2004-08-01), Aoki et al.
patent: 2005/0084504 (2005-04-01), Aoki et al.
patent: 2005/0112146 (2005-05-01), Graham
patent: 19852981 (2000-05-01), None
patent: 1477183 (2005-02-01), None
patent: 2272697 (1994-05-01), None
patent: WO 93/05800 (1993-04-01), None
patent: WO 94/00481 (1993-06-01), None
patent: WO 94/00081 (1994-01-01), None
patent: WO 94/28922 (1994-06-01), None
patent: WO 94/15629 (1994-07-01), None
patent: WO 94/28923 (1994-12-01), None
patent: WO 95/17904 (1995-07-01), None
patent: WO 95/30431 (1995-11-01), None
Tse et al., ‘Preperation and Characterisation of Homogenous Neurotoxin Type A FromClostridium botulinum’ Eur. J. Biochem. vol. 122, No. 3 (1982), pp. 493-500.
Arthritis. Medline Plus Medical Encyclopedia. Feb. 2010. [Retrieved Jun. 13, 2010]. Retrieved from the Internet <http://www.nlm.nih.gov/medlineplus/ency/article/001243.htm.>.
“Botulinum-Toxin hilft bei Augenleiden”(Dec. 1986).
“Cervical Dystonia”[www.fpnotebook.com/NEU151.htm]; pp. 1-2, (retrieved Sep. 3, 2003).
Communication from the European Patent Office dated Sep. 27, 2007.
“Enzyme Linked Immuno Sorbent Assays(ELISAS)to Detect Botulinum Toxins Using High Titer-Rabbit Anti-Sera”Botulinum and Tetanus Neurotoxins, Plenum Press, (1993).
“Hyperesthesia Associated with Hyperextension Injuries of the Neck”Injury, vol. 18, No. 4; p. 234, Abstract only, 1987.
“Porton Refocuses on Pharmaceuticals”Scrip, No. 1871, 10 (vol. 9, No. 1993).
Adenis, J.P. et al., “Traitement des Spasmes Faciaux Par La Toxine Botulique a”J.Fr. Ophtalmal., vol. 13, No. 5; pp. 259-264, (1990).
Ambache,J. Physiol., 108; pp. 127-141, (1949).
Ambache, N., “A Further Survey of the Action of Clostridium Botulinum Toxin Upon Different Types of Autonomic Nerve Fibre”J. Physiol.,113; pp. 1-17, (1951).
Borodic et al., “Botulinum B Toxin as an Alternative to Bot. A Toxin: A Histologic Study,”Oph. Plastic and Recon. Sur., vol. 9(3); pp. 182-190 • 1993.
Clark, J.B., “Cervical Dystonia Following Exposure to High-G Forces”Aviat. Space Environ. Me., vol. 61; pp. 935-937, (1990).
Das, T.K. et al., “Effect of treatment with Botulinum toxin on spasticity”Postgraduate Medical Journal, vol. 65; pp. 208-210, (1989).
Habermann “Foreword”Botulinum and Tetanus Neurotoxins, published by Plenum Press; pp. v-ix, (1993).
Dykstra, D. et al., “Treatment of Detrusor-Sphincter Dyssynergia with Botulinum A Toxin: A Double-Blind Study”Arch. Phys. Med. Rehabil., vol. 71; pp. 24-26, (Jan. 1990).
Foster, K.A., “New Wrinkle on Pain Relief: Re-Engineering Clostridial Neurotoxins for Analgesics”Drug Discovery Today, vol. 10, No. 8; pp. 563-569, (Apr. 2005).
Greene, et al., “Development of Antibodies to Botulinum Toxin Type A in Patients with Torticollis Treated wiht Injections of Botulinum Toxin Type A”Botulinum and Tetanus Neurotoxins, Plenum Press; pp. 651-654, (1993).
Greene, et al., “Use of Botulinum Toin Type F Injection to Treat Torticollis in Patients with Immunity of Botulinum Toxin type A”Movement Disorders, vol. 8, No. 4; pp. 479-483, (1993).
Hambleton, P., “Clostridum Botulinum Toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use”J. Neurol., vol. 239, No. 1; pp. 16-20, (1992).
Harper, K.E., et al., “Frey's Syndrome”International Journal of Dermatology, vol. 25, No. 8; pp. 524-526, (Oct. 1986).
Hatherway, C.L., “Bacterial Sources of Clostridial Neurotoxins”Botulinum Neurotoxin and Tetanus Toxin Academic Press, pp. 4-24, (1989).
Heneson, “Deadly toxin calms excited muscles,”Science, p. 24 (1990).
Jankovic, et al., “Therapy with Botulinum Toxin”Botulinum and Tetanus Neurotoxins, Plenum Press, (1993).
Jankovic et al., “Therapeutic Uses of Botulinum Toxin” ,The New Eng. J. of Med., p. 1186 (Apr. 25, 1991).
Jenzer, G., et al., “Type B Botulism, Report on Mild Courses with Predominantly Autonomic Nervous Impairement”Schweiz. Med. Wschr, vol. 104; pp. 685-693, (1974), with English translation.
Khalafalla, et al., “Botulinum Toxin and Sweating”J. Neurology, Neurosurgery and Psychiatry, 57; pp. 1437-1438, (1994).
Knight, “Botulinum Toxin Types A, B and D Inhibit Catecholamine Secretion from Bovine Adrenal Medullary Cells,”FEBS Lett., vol. 207(2); pp. 222-228, 1986.
Kondo et al., “Modification of the Action of Pentagastrin on acid secretion by botulinum toxin”Experientia, vol. 33(6); pp. 750-751, 1977.
Konstazer, A. et al., “Lokale Injektionsbehandlung mit Botulinum-Toxin A bei schwerer Arm-und Beinspastik”Der Nervenarzt, vol. 64(8); pp. 517-523, (Aug. 1993).
Laccourreye, et al., “Treatment of Frey's Syndrome in Topical 2% Diphemanil Methylsulfate(Prantal):A Double-Blind Evaluation of 15 Patients”Laryngoscope, vol. 100; pp. 651-653, (1990).
Ludlow, et al., “Therapeutic Uses of Type F Botulinum Toxin”Letter to New England Journal of Medicine, vol. 326, No. 5; pp. 349-350, (Jan. 1992).
Memin, et al., “Traitement de la Spasticité 212-214, par la Toxine Botulique”Rev. Neurol., vol. 148(3); pp. 212-214, (1992).
Montecucco, C., et al., “Botulinum Neurotoxins: Mechanism of Action and Therapeutic Applications”Mol. Med. Today, vol. 2, No. 10; pp. 418-424, (Oct. 1996).
Moyer, E., et al. “Botulinum Toxin Type B: Experimental and Clinical Experience”Therapy with Botulinum Toxin, Jankovic J. and Hallett, M., ed., Dekker Publishers; New York, NY; pp. 71-85, (Feb. 1994).
Price et al., “A Comparative Study of Tear Secretion in Blepharospasm and Hemifacial Spasm Patients treated with Botulinum Toxin,”J. of Clin. Neuro, vol. 13(1); pp. 67-71 (1993).
Ransom, G.M., et al., “Enzyme-Linked Immunosorbent Assays(ELISAs)to Detect Botulinum Toxins Using High Titer Rabbit Anti-Sera”Botulinum and Tetanus Neurotoxins, Plenum Press; pp. 449-462, (1993).
Ruusuvaara, P and Setala, K., “Long-term Treatment of Involuntary Facial Spasms Using Botulinum Toxin”Acta Opthal., vol.
Aoki K. Roger
Carlson Steven R.
Grayston Michael W.
Leon Judith M.
Allergan Inc.
Condino Debra
Gibson Hal
Gupta Anish
LandOfFree
Use of the neurotoxic component of a botulinum toxin for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of the neurotoxic component of a botulinum toxin for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of the neurotoxic component of a botulinum toxin for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4299318